Novo Nordisk (NVO) is suing Hims & Hers (HIMS) for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S., CNBC’s Annika Kim Constantino reports. Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents, and is seeking to recover damages. The move escalates the feud between Novo and Hims, which said on Saturday it will stop offering its newly launched obesity pill copycat after facing scrutiny from federal regulators and legal threats from the Danish drugmaker.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Hims & Hers price target lowered to $21 from $26 at BofA
- HIMS Stock Drops, NVO Jumps after Hims & Hers Halts Selling $49 Wegovy Copy
- Hims & Hers (HIMS) Shares Sink 16% as FDA Crackdown Halts Wegovy Copycat Pill
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 8
- FDA intends to ‘take action’ against non-FDA-approved GLP-1 drugs